Kevin Hascup Lab

Our laboratory takes a geroscience approach to understanding biological processes that contribute to the pathogenesis of Alzheimer’s disease. The long-term goals of our laboratory are to:

1. identify nonpharmacological interventions that target insulin and glutamate signaling pathways that prevent or alleviate cognitive decline and
2. elucidate their mechanisms of action in order to identify pharmacological targets for treating Alzheimer’s disease and related dementias.

To address these goals, our laboratory has several ongoing research interests examining the contribution of body temperature, glutamatergic neurotransmission, and glucose homeostasis on cognitive decline in mouse models of Alzheimer’s disease as well as extended longevity. These parameters are assessed by using innovative whole animal and molecular biological techniques to measure in vivo neurotransmitter dynamics, cognitive performance, and metabolism.

Current projects

•    Neurotransmitter dysregulation in AD (NIH R01 AG057767)
•    Cell senescence in aging and AD (NIH R01 AG061937)
•    COVID-19 Infection on AD (NIH R01 AG061937-S3)
•    Core body temperature on AD pathogenesis
•    Model organism development for AD, aging, and COVID-19
•    Cell senescence in epilepsy